In Vivo Star Anti-Human HLA-DR/DP/DQ Antibody
英诺赛图(InnoCyto)的 In Vivo Star Anti-Human HLA-DR/DP/DQ Antibody(克隆 F3.3) 为鼠源 IgG1 Kappa 抗体,靶向 Human。提供 1 mg、5 mg、25 mg 规格,目录价 ¥1,085 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 In Vivo Star Anti-Human HLA-DR/DP/DQ Antibody(克隆 F3.3) 为鼠源 IgG1 Kappa 抗体,靶向 Human。提供 1 mg、5 mg、25 mg 规格,目录价 ¥1,085 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
518501 | 1 mg | ¥1,085
518502 | 5 mg | ¥2,712
518503 | 25 mg | ¥7,458
Product Details
Application|Direct ELISA, functional assay, Flow Cytometry
Target Name|Major Histocompatibility complex II, human leukocyte antigen, HLA, MHC class II
Product Description|In vivo Grade Recombinant Anti-Human HLA-DR/DP/DQ Monoclonal Antibody
Regulatory Status|RUO
Endotoxin
Storage Conditions|4ºC
Recommended Usage|This product is suitable in in vitro functional assays or in vivo on human cells used in animal models. Optimal amounts need to be determined empirically for each experiment.
See All Formats|Clone F3.3
Background Information
HLA-DR, HLA-DP, and HLA-DQ are the classical human leukocyte antigen (HLA) class II molecules that play a central role in the adaptive immune system by presenting extracellular peptide antigens to CD4⁺ T helper cells. Encoded within the MHC class II region on chromosome 6, these molecules are expressed primarily on professional antigen-presenting cells such as dendritic cells, macrophages, and B cells. Their main function is to initiate immune responses against pathogens, maintain tolerance to self-antigens, and regulate immune-mediated signaling within tissues.
Structurally, HLA class II molecules are heterodimers composed of two non-covalently associated transmembrane glycoprotein chains: an alpha (α) chain and a beta (β) chain. The α1 and β1 domains form the peptide-binding groove, which accommodates peptides typically 13–25 amino acids long. Each HLA-II is encoded by distinct gene pairs: HLA-DRA and -DRB for HLA-DR, HLA-DPA and -DPB for HLA-DP, and HLA-DQA and -DQB for HLA-DQ. These molecules assemble in the endoplasmic reticulum and are stabilized by the invariant chain (Ii), which prevents premature peptide binding. In late endosomes, Ii is degraded, and peptides generated from extracellular antigens are loaded onto HLA-II molecules with the assistance of the peptide editor HLA-DM before being presented on the cell surface.
The ligands for HLA-DR, DP, and DQ are peptide antigens derived mainly from exogenous proteins internalized by antigen-presenting cells. These peptide-MHC II complexes are recognized by the T cell receptor (TCR) on CD4⁺ T helper cells, triggering their activation and cytokine release. This interaction bridges innate and adaptive immunity, shaping both humoral and cell-mediated responses.
Polymorphisms in HLA-DR, DP, and DQ genes have profound effects on disease susceptibility. Specific allelic variants are associated with autoimmune disorders, including type 1 diabetes (DR3-DQ2, DR4-DQ8), rheumatoid arthritis (DRB1*04), celiac disease (DQ2 and DQ8), and multiple sclerosis (DRB1*15). These associations arise because certain variants preferentially present self-peptides that activate autoreactive T cells. Conversely, HLA-II polymorphism contributes to protection against infections by broadening the range of peptides that can be presented to the immune system.
In therapeutic contexts, HLA-DR/DP/DQ typing is critical for transplantation compatibility, as mismatches can lead to graft rejection or graft-versus-host disease. Beyond transplantation, HLA-II molecules are vital in predicting immune responses to vaccines and designing antigen-specific immunotherapies. Advances in peptide-based vaccination and autoimmune disease treatments increasingly rely on identifying the precise peptide-HLA-II combinations that drive protective or pathogenic immune activation. Thus, HLA-DR, DP, and DQ remain central to understanding immune recognition, tolerance, and therapeutic modulation in human health and disease.
Data Sheets
Cat # Size Price Quantity 5185011 mg Add to Cart5185025 mg Add to Cart51850325 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). In Vivo Star Anti-Human HLA-DR/DP/DQ Antibody(518501)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/in-vivo-star-anti-human-hla-dr-dp-dq-antibody.html.
TeleVM. (2026, November 12). In Vivo Star Anti-Human HLA-DR/DP/DQ Antibody(518501). 产品目录. https://www.suprotek.cn/products/item/in-vivo-star-anti-human-hla-dr-dp-dq-antibody.html
@misc{biocsp_item_in_vivo_star_anti_human_hla_dr_dp_dq_antibody,
title = {In Vivo Star Anti-Human HLA-DR/DP/DQ Antibody(518501)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/in-vivo-star-anti-human-hla-dr-dp-dq-antibody.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源